DNA vaccines for SARS-CoV-2: toward third-generation vaccination era
ABSTRACT Introduction: Coronavirus outbreak 2019 (COVID-19) has affected all the
corners of the globe and created chaos to human life. In order to put some control on the …
corners of the globe and created chaos to human life. In order to put some control on the …
The development of DNA vaccines against SARS-CoV-2
Background The COVID-19 pandemic exerted significant impacts on public health and
global economy. Research efforts to develop vaccines at warp speed against SARS-CoV-2 …
global economy. Research efforts to develop vaccines at warp speed against SARS-CoV-2 …
Switchable targeting of solid tumors by BsCAR T cells
AV Stepanov, RS Kalinin… - Proceedings of the …, 2022 - National Acad Sciences
The development of chimeric antigen receptor (CAR) T cell therapy has become a critical
milestone in modern oncotherapy. Despite the remarkable in vitro effectiveness, the problem …
milestone in modern oncotherapy. Despite the remarkable in vitro effectiveness, the problem …
The use of electroporation to deliver DNA-based vaccines
DN Kisakov, IM Belyakov, LA Kisakova… - Expert Review of …, 2024 - Taylor & Francis
Introduction Nucleic acids represent a promising platform for creating vaccines. One
disadvantage of this approach is its relatively low immunogenicity. Electroporation (EP) is an …
disadvantage of this approach is its relatively low immunogenicity. Electroporation (EP) is an …
DNA Vaccines: Their formulations, engineering and delivery
M Kozak, J Hu - Vaccines, 2024 - mdpi.com
The concept of DNA vaccination was introduced in the early 1990s. Since then,
advancements in the augmentation of the immunogenicity of DNA vaccines have brought …
advancements in the augmentation of the immunogenicity of DNA vaccines have brought …
Dendrimer-mediated delivery of DNA and RNA vaccines
LA Kisakova, EK Apartsin, LF Nizolenko, LI Karpenko - Pharmaceutics, 2023 - mdpi.com
DNA and RNA vaccines (nucleic acid-based vaccines) are a promising platform for vaccine
development. The first mRNA vaccines (Moderna and Pfizer/BioNTech) were approved in …
development. The first mRNA vaccines (Moderna and Pfizer/BioNTech) were approved in …
Advances in vaccine delivery systems against viral infectious diseases
Although vaccines are available for many infectious diseases, there are still unresolved
infectious diseases that threaten global public health. In particular, the rapid spread of …
infectious diseases that threaten global public health. In particular, the rapid spread of …
Antigen bivalency of antigen-presenting cell-targeted vaccines increases B cell responses
DM Hinke, TK Andersen, RP Gopalakrishnan… - Cell reports, 2022 - cell.com
Antibodies are important for vaccine efficacy. Targeting antigens to antigen-presenting cells
(APCs) increases antibody levels. Here, we explore the role of antigen valency in MHC class …
(APCs) increases antibody levels. Here, we explore the role of antigen valency in MHC class …
Therapeutic vaccines for cancer immunotherapy
J Wang, M Mamuti, H Wang - ACS Biomaterials Science & …, 2020 - ACS Publications
The rapid development of nanobiotechnology has enabled progress in therapeutic cancer
vaccines. These vaccines stimulate the host innate immune response by tumor antigens …
vaccines. These vaccines stimulate the host innate immune response by tumor antigens …
Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza
Conventional influenza vaccines focus on hemagglutinin (HA). However, antibody
responses to neuraminidase (NA) have been established as an independent correlate of …
responses to neuraminidase (NA) have been established as an independent correlate of …